- Home
- CAPR vs CAN Comparison
CAPR vs CAN Comparison
Compare CAPR & CAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CAN
- Stock Information
- Founded
- CAPR 2005
- CAN 2013
- Country
- CAPR United States
- CAN Singapore
- Employees
- CAPR N/A
- CAN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CAN Semiconductors
- Sector
- CAPR Health Care
- CAN Technology
- Exchange
- CAPR Nasdaq
- CAN Nasdaq
- Market Cap
- CAPR 324.6M
- CAN 330.5M
- IPO Year
- CAPR N/A
- CAN 2019
- Fundamental
- Price
- CAPR $6.08
- CAN $0.81
- Analyst Decision
- CAPR Strong Buy
- CAN Strong Buy
- Analyst Count
- CAPR 8
- CAN 6
- Target Price
- CAPR $24.75
- CAN $2.50
- AVG Volume (30 Days)
- CAPR 1.2M
- CAN 25.3M
- Earning Date
- CAPR 11-12-2025
- CAN 08-14-2025
- Dividend Yield
- CAPR N/A
- CAN N/A
- EPS Growth
- CAPR N/A
- CAN N/A
- EPS
- CAPR N/A
- CAN N/A
- Revenue
- CAPR $13,392,150.00
- CAN $345,360,000.00
- Revenue This Year
- CAPR N/A
- CAN $90.25
- Revenue Next Year
- CAPR $7,894.07
- CAN $42.94
- P/E Ratio
- CAPR N/A
- CAN N/A
- Revenue Growth
- CAPR N/A
- CAN 82.40
- 52 Week Low
- CAPR $4.59
- CAN $0.53
- 52 Week High
- CAPR $23.40
- CAN $3.27
- Technical
- Relative Strength Index (RSI)
- CAPR 40.13
- CAN 59.68
- Support Level
- CAPR $5.97
- CAN $0.77
- Resistance Level
- CAPR $6.57
- CAN $0.85
- Average True Range (ATR)
- CAPR 0.38
- CAN 0.04
- MACD
- CAPR 0.03
- CAN 0.01
- Stochastic Oscillator
- CAPR 36.70
- CAN 77.32
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.